Analysis of HTA decisions, pricing and access.
Sourced briefings on HTA, the EU JCA, pricing policy and AI in evidence generation.
Cancer Drugs Fund and IMF: NICE managed access from entry to exit
How the Cancer Drugs Fund and Innovative Medicines Fund work in 2026: NICE managed access entry criteria, data collection agreements and CDF exit.
Read the analysisNICE technology appraisal in 2026: process, threshold and what is new
NICE technology appraisal in 2026: the STA process end to end, the new £25,000 to £35,000 threshold, severity weights, EQ-5D-5L and the MHRA-NICE pathway.
Read the analysisNICE and the UK EQ-5D-5L value set: what PMG51 changes
NICE EQ-5D-5L value set explained: PMG51 rules, 3L to 5L mapping, how utilities, ICERs and severity shortfall move, transition dates and evidence planning.
Read the analysisThe SMC submission guide: how Scotland assesses new medicines in 2026
A practitioner guide to SMC submissions in 2026: NDC and SMC Committee, NPAF v4.0, PACE, ultra-orphan, interim acceptance, PASAG and decision data.
Read the analysisAWMSG in 2026: a practitioner guide to medicines access in Wales
How AWMSG works in 2026: when Wales follows NICE, panel routing, full, interim and limited assessment, CASWG commercial arrangements and budget impact.
Read the analysisThe Irish reimbursement journey in 2026: from application to listing
The Irish medicines reimbursement journey in 2026: the 2013 Act, NCPE assessment, HIQA methods, €20,000 and €45,000 per QALY, FASPM timelines and HSE decisions.
Read the analysisUS MFN drug pricing: what it means for UK and European launches
US MFN drug pricing explained: GLOBE, GUARD and GENEROUS, reference baskets, the GDP (PPP) adjuster and what it means for UK, Irish and EU launch prices.
Read the analysisJCA PICO scoping: how it works and what the first reports show
How PICO scoping works in the EU joint clinical assessment, what the first published JCA reports show, and how to plan SLRs and indirect comparisons for it.
Read the analysisNICE severity modifier explained: shortfall, weights and 2026 changes
NICE severity modifier explained: absolute and proportional QALY shortfall, the 1.2 and 1.7 weights, a worked example and the 2026 EQ-5D-5L changes.
Read the analysisPopulation-adjusted indirect comparisons: MAIC, STC and ML-NMR
Population-adjusted indirect comparisons for HTA: how MAIC, STC and ML-NMR work, what NICE TSD 18 and the EU JCA guidelines require, and how to choose a method.
Read the analysisOne evidence plan for NICE and the EU JCA
How NICE and EU JCA evidence requirements align and diverge, and how to design one SLR and indirect treatment comparison programme to serve both.
Read the analysisNCPE rapid review or full HTA? How Irish reimbursement really works
NCPE rapid review vs full HTA explained: what triggers a full assessment, HIQA 2025 methods, the €20,000 and €45,000 thresholds, and the HSE decision process.
Read the analysisSMC and AWMSG: HTA in Scotland and Wales, and how it differs from NICE
How SMC and AWMSG assess new medicines: PACE, modifiers, ultra-orphan and interim acceptance, PASAG, Wales commercial arrangements, and differences from NICE.
Read the analysisSurvival extrapolation for HTA: TSD 14 to flexible and cure models
Survival extrapolation for HTA: NICE DSU TSD 14 and TSD 21, hazard plots, spline and cure models, external data, treatment effect waning and immature data.
Read the analysisAdapting a global cost-effectiveness model for NICE and NCPE
How to adapt a global cost-effectiveness model for NICE and NCPE: reference cases, discounting, EQ-5D, local costs, severity, budget impact and validation.
Read the analysisWhen and how to update a systematic literature review for HTA
When and how to update a systematic literature review for HTA: BMJ consensus, Cochrane and PRISMA guidance, NICE and EU JCA search rules, living SLRs and AI.
Read the analysisGLP-1s in 2026: the price fell, the access gap did not
HTA and payer decisions for GLP-1 obesity medicines across the US, England, France, Germany and Ireland.
Read the analysisOne Regulation. 27 Speeds. The JCA Readiness Index
Which EU member states are ready for joint clinical assessment, and what that means for 2027 launches.
Read the analysisAI in global HTA: where the guidance stands
Only one of eleven major HTA bodies has a full position statement on AI in evidence generation.
Read the analysis
One evidence package, thirteen answers.
Our 21-page guide compares thirteen HTA systems across the UK, Europe and Canada, with 16 exhibits and full references. Subscribe to Evidaxia Briefing, our sourced analysis of market access, HTA decisions, evidence and health policy, and the guide downloads the moment you subscribe.
Want a country-by-country read-out for your asset?
Start with a free, no-obligation 30-minute call with a senior consultant.